- Type
- award, contract
- Procedure
- Direct award
- Ref. number
- 039802-2026
- Estimated value
- 180,000 GBP
The Clinical Biotechnology Centre (CBC) has recently validated a GMP-compliant recombinant adeno‑associated viral vector (rAAV) manufacturing platform process to support UK academic clients in transitioning their gene th…
erapy programmes from research into human clinical trials. The work took over four years of intensive effort, including initial process development, iterative process optimisation and scale‑up to ensure suitability for GMP technology transfer. Critical starting and raw materials were selected and ap
proved for use on the platform, as well as determining the optimal process parameters to ensure consistent performance. The validated platform process is now installed within the CBC’s GMP clean room viral vector manufacturing suites. As rA